文献速递临床试验与 GCP真实世界研究与卫生经济

减轻财务毒性影响(LIFT):一项多站点单臂试验方案,考察财务导航对农村和非农村地区成年癌症患者财务毒性的影响

Lessening the Impact of Financial Toxicity (LIFT): a protocol for a multi-site, single-arm trial examining the effect of financial navigation on financial toxicity in adult patients with cancer in rural and non-rural settings.
PubMed 文献 · Trials · 2022-10-03

LIFT研究是一项在美国北卡罗来纳州九个肿瘤诊疗机构开展的多站点2期单臂前后对照试验,计划入组780例成年癌症患者,评估财务导航对财务毒性(主要结局,采用COST量表)、健康相关生活质量及患者报告的因费用延迟或放弃医疗的影响,并评估实施结局。

要点

  • LIFT为多站点2期单臂前后对照试验,在九个肿瘤诊疗机构开展,计划入组780例患者。
  • 财务导航由全职或兼职财务导航员提供,包括系统筛查、连接财务资源及持续随访追踪。
  • 主要结局为财务毒性变化,采用经验证的COST量表测量。

核心结论

  • 该研究旨在评估财务导航在多样化肿瘤诊疗机构中的实施情况和有效性,为不断增长的证据提供补充。

研究设计与样本

  • LIFT研究是一项多站点2期临床试验,采用前后对照单臂干预设计,考察财务导航对成年癌症患者财务毒性的影响。
  • 研究在美国北卡罗来纳州九个肿瘤诊疗机构开展,站点在地理位置(五个农村、四个非农村)、规模(21至974张住院床位)和所有权结构(政府、非营利)方面各不相同。
  • 计划在约2年内共入组780例患者;合格患者须年满18岁、在过去5年内确诊任何类型癌症或处于晚期疾病状态,且癌症相关财务困扰筛查阳性。

主要发现

  • 财务导航由全职或兼职财务导航员提供,包括三个组成部分:系统财务毒性筛查识别与全面入组评估;通过经过培训的肿瘤财务导航员将经历财务毒性的患者与财务支持资源连接;由财务导航员进行持续随访和电子追踪患者进展与结局。
  • 将通过评估财务毒性变化(主要结局,采用经验证的COST量表)、健康相关生活质量(PROMIS全球健康问卷)以及患者报告的因费用延迟或放弃医疗来测量干预有效性。
  • 还评估干预后患者和利益相关者报告的实施和服务结局,包括采纳、保真度、可接受性、成本、以患者为中心和及时性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Almost half of the patients with cancer report cancer-related financial hardship, termed "financial toxicity" (FT), which affects health-related quality of life, care retention, and, in extreme cases, mortality. This increasingly prevalent hardship warrants urgent intervention. Financial navigation (FN) targets FT by systematically identifying patients at high risk, assessing eligibility for existing resources, clarifying treatment cost expectations, and working with patients and caregivers to develop a plan to cope with cancer costs. This trial seeks to (1) identify FN implementation determinants and implementation outcomes, and (2) evaluate the effectiveness of FN in improving patient outcomes. METHODS: The Lessening the Impact of Financial Toxicity (LIFT) study is a multi-site Phase 2 clinical trial. We use a pre-/post- single-arm intervention to examine the effect of FN on FT in adults with cancer. The LIFT trial is being conducted at nine oncology care settings across North Carolina in the United States. Sites vary in geography (five rural, four non-rural), size (21-974 inpatient beds), and ownership structure (governmental, non-profit). The study will enroll 780 patients total over approximately 2 years. Eligible patients must be 18 years or older, have a confirmed cancer diagnosis (any type) within the past 5 years or be living with advanced disease, and screen positive for cancer-related financial distress. LIFT will be delivered by full- or part-time financial navigators and consists of 3 components: (1) systematic FT screening identification and comprehensive intake assessment; (2) connecting patients experiencing FT to financial support resources via trained oncology financial navigators; and (3) ongoing check-ins and electronic tracking of patients' progress and outcomes by financial navigators. We will measure intervention effectiveness by evaluating change in FT (via the validated Comprehensive Score of Financial Toxicity, or COST instrument) (primary outcome), as well as health-related quality of life (PROMIS Global Health Questionnaire), and patient-reported delayed or forgone care due to cost. We also assess patient- and stakeholder-reported implementation and service outcomes post-intervention, including uptake, fidelity, acceptability, cost, patient-centeredness, and timeliness. DISCUSSION: This study adds to the growing evidence on FN by evaluating its implementation and effectiveness across diverse oncology care settings. TRIAL REGISTRATION: ClinicalTrials.gov NCT04931251. Registered on June 18, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wheeler SB, Biddell CB, Manning ML, et al. Lessening the Impact of Financial Toxicity (LIFT): a protocol for a multi-site, single-arm trial examining the effect of financial navigation on financial toxicity in adult patients with cancer in rural and non-rural settings. Trials. 2022. PMID: 36192802. doi:10.1186/s13063-022-06745-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。